Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Jounce Therapeutics, Inc.
Study ID
NCT04319224
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vopratelimab — DRUG
    Specified dose on specified days
  • Ipilimumab — DRUG
    Specified dose on specified days
  • Nivolumab — DRUG
    Specified dose on specified days

Study Details

JTX-2011-R01 is an open label, multicenter, rollover study that is designed to provide continued access to vopratelimab for eligible subjects with advanced solid tumor malignancies who have previously participated in a vopratelimab study (the parent study).

Key Dates

Start date
Mar 10, 2020
Status verified
May 2024
Primary completion
Jan 3, 2023
Completion
Jan 3, 2023

Study Design

Enrollment
4 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vopratelimab
    Participants will continue to receive vopratelimab monotherapy per parent protocol.
  • Experimental: Vopratelimab with ipilimumab
    Participants will continue to receive vopratelimab in combination with ipilimumab per parent protocol.
  • Experimental: Vopratelimab with nivolumab
    Participants will continue to receive vopratelimab in combination with nivolumab per parent protocol.

Primary Outcome Measure

Percentage of Subjects With Adverse Events (AEs) [ Time Frame: Approximately 34 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110-
The University of Texas - MD Anderson Cancer CenterHoustonTexas77030-
University of Virginia Health SystemsCharlottesvilleVirginia22908-

Find similar trials in St Louis, MO

By research site
Washington University School of Medicine· St Louis, MOThe University of Texas - MD Anderson Cancer Center· Houston, TXUniversity of Virginia Health Systems· Charlottesville, VA

Related Studies